ATE406896T1 - Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten - Google Patents

Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten

Info

Publication number
ATE406896T1
ATE406896T1 AT03713475T AT03713475T ATE406896T1 AT E406896 T1 ATE406896 T1 AT E406896T1 AT 03713475 T AT03713475 T AT 03713475T AT 03713475 T AT03713475 T AT 03713475T AT E406896 T1 ATE406896 T1 AT E406896T1
Authority
AT
Austria
Prior art keywords
dopamine
monoester
asymmetrically substituted
receptor agonist
agonist prodrugs
Prior art date
Application number
AT03713475T
Other languages
German (de)
English (en)
Inventor
Durk Dijkstra
Hakan Wikstrom
Original Assignee
Darpharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0200478A external-priority patent/SE0200478D0/xx
Priority claimed from SE0200474A external-priority patent/SE0200474D0/xx
Application filed by Darpharma Inc filed Critical Darpharma Inc
Application granted granted Critical
Publication of ATE406896T1 publication Critical patent/ATE406896T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/18Ring systems of four or more rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03713475T 2002-02-15 2003-02-14 Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten ATE406896T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200478A SE0200478D0 (sv) 2002-02-15 2002-02-15 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine D1 receptor agonist A-86929
SE0200474A SE0200474D0 (sv) 2002-02-17 2002-02-17 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine D1 receptor agonists Dihydrexidine and Dinapsoline

Publications (1)

Publication Number Publication Date
ATE406896T1 true ATE406896T1 (de) 2008-09-15

Family

ID=27759833

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03713475T ATE406896T1 (de) 2002-02-15 2003-02-14 Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten

Country Status (11)

Country Link
US (1) US7220754B2 (enExample)
EP (1) EP1480647B1 (enExample)
JP (1) JP2005526728A (enExample)
AT (1) ATE406896T1 (enExample)
AU (1) AU2003217430B2 (enExample)
CA (1) CA2476115A1 (enExample)
DE (1) DE60323339D1 (enExample)
DK (1) DK1480647T3 (enExample)
ES (1) ES2314189T3 (enExample)
NO (1) NO20043634L (enExample)
WO (1) WO2003070245A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
CN1964713A (zh) * 2003-12-23 2007-05-16 达法尔摩公司 多巴胺-受体结合化合物的共同使用
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
US8596306B2 (en) * 2005-10-27 2013-12-03 Synthetic Gas Solutions, Llc Perfluorocarbon gas insufflation
EP2010541A2 (en) * 2006-02-21 2009-01-07 Purdue Research Foundation Trans-fused chromenoisoquinolines, synthesis and methods for use
WO2010124005A1 (en) 2009-04-21 2010-10-28 Purdue Research Foundation Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor
CN104981472A (zh) * 2012-11-08 2015-10-14 辉瑞大药厂 杂芳族化合物及其作为多巴胺d1配体的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340600A (en) * 1980-05-22 1982-07-20 Smithkline Corporation Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines
US4282227A (en) * 1980-05-22 1981-08-04 Smithkline Corporation Renal vasodilating 3,4-dihydroxyphenyltetrahydrothienopyridines
JPH02138A (ja) * 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd L‐ドーパ誘導体
US5047536A (en) * 1989-03-17 1991-09-10 Purdue Research Foundation Hexahydrobenzo(A)phenanthridine compounds
IE912999A1 (en) 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
DE69334206D1 (de) * 1992-05-26 2008-04-03 Purdue Research Foundation Substituierte hexahydrobenzo(a) phenanthridine
ATE233765T1 (de) 1993-04-06 2003-03-15 Abbott Lab Tetracyclische verbindungen als dopamin-agonisten
WO1996002513A1 (en) 1994-07-15 1996-02-01 Purdue Research Foundation Optically active isomers of dihydrexidine and its substituted analogs
WO1997006799A1 (en) * 1995-08-18 1997-02-27 Purdue Research Foundation Novel fused isoquinolines as dopamine receptor ligands

Also Published As

Publication number Publication date
AU2003217430A1 (en) 2003-09-09
DE60323339D1 (de) 2008-10-16
CA2476115A1 (en) 2003-08-28
WO2003070245A1 (en) 2003-08-28
US7220754B2 (en) 2007-05-22
EP1480647B1 (en) 2008-09-03
US20050096469A1 (en) 2005-05-05
NO20043634L (no) 2004-11-11
EP1480647A4 (en) 2005-07-13
AU2003217430B2 (en) 2008-10-23
DK1480647T3 (da) 2009-01-26
JP2005526728A (ja) 2005-09-08
EP1480647A1 (en) 2004-12-01
ES2314189T3 (es) 2009-03-16
WO2003070245B1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
NZ514409A (en) C7 ester substituted taxanes as antitumor agents
DK1689233T3 (da) Bicykliske inhibitorer af MEK
EP2613782A4 (en) INDAZONE DERIVATIVES AS ERK HEMMER
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
AR040870A1 (es) Compuestos inhibidores de proteinquinasas y composicion farmaceutica que los comprende
ECSP014097A (es) Derivados de tiofeno utiles como agentes anticancerosos
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
AR021482A1 (es) Compuestos de 4-carboxiamino-1,2,3,4-tetrahidroquinolinas, composiciones farmaceuticas, kit, y uso de los mismos.
ECSP088082A (es) Derivados de piridazina
GT200100196A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7.
CR20140368A (es) Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036)
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
UY27633A1 (es) Nuevos ésteres de ácido fluoreno-carbox ílicos, procedimientos para su preparación así como su utilización en calidad de medicamentos
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
AR058296A1 (es) Inhibidores de histona desacetilasa y composicion farmaceutica
CO5590918A2 (es) Formulaciones
ECSP088229A (es) Derivados de pirazolona como inhibidores de 11-beta hsd1
GB2420781B (en) Aminopyrones and their use as ATM inhibitors
AR028624A1 (es) Heterociclilalquilaminas como antagonistas de receptores muscarinicos
BRPI0409105A (pt) análogos de quinobenzoxazina substituìdos
AR016422A1 (es) Compuestos de esteres ciclicos de piperidinilaminometil trifluorometilo como antagonista de la sustancia p; composiciones farmaceuticas y procedimientos detratamiento.
ATE406896T1 (de) Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten
AR004512A1 (es) Derivados de benzotiazolona, procedimientos para su preparacion, compuestos intermediarios utiles para llevar a cabo dicho procedimiento ycomposiciones farmaceuticas que comprenden dichos derivados
ATE240299T1 (de) Diester prodrugs von decahydroischinoline-3- carbonsäure
CA2589438C (en) Treatment of inflammatory bowel disease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties